12 results about "Conjugated vaccines" patented technology

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The disclosures of the invention arc directed to the manufacture of effective, affordable vaccines that arc globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA CO VID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.l, BA.2, and BA.4 / BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

The invention discloses a preparation method of a proteoglycan protein conjugate carrying a specified connection site. The method comprises the following steps: carrying out recombinant expression on a recombinant tetanus toxin heavy chain C fragment rTTHc containing a Sortase A 7M ligase recognition sequence, introducing O, O '-(ethane-1, 2-diyl) bis (hydroxylamine) as a nucleophilic reagent into the C tail end of the rTTHc under the action of ligase Sortase A 7M, and carrying out specific condensation reaction on the C tail end of the rTTHc as a unique chemical reaction site and polysaccharide carrying an aldehyde group functional group to obtain the tetanus toxin heavy chain C fragment rTTHc. Therefore, polysaccharide protein conjugates with definite polysaccharide and protein connection sites are produced. According to the invention, the problem that the key antigen epitope of the carrier protein and the heterogeneity of the product are possibly damaged by the traditional random modification strategy is solved, the antigen epitope of the carrier protein is prevented from being damaged to a great extent, and a reliable technical scheme is provided for preparing the polysaccharide conjugate vaccine with high quality and high immunogenicity.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

This invention provides a means to inactivate the inherent toxicity of tetanus toxin and produce a safe and effective vaccine. [Solution] This specification provides engineered non-catalytic, non-toxic tetanus toxin variants and methods for using such engineered tetanus toxin variants as low-dose prophylactic vaccines that are more effective than non-toxic and their respective chemically inactivated toxoids. In addition, this specification provides conjugate vaccine carriers containing engineered tetanus toxin variants and methods for using such conjugate vaccines to induce a T-cell-dependent immunomemory response that can target a broad range of microbial pathogens as a single vaccine.

The application discloses a preparation method of a mycobacterium bovis polysaccharide antigen, the polysaccharide antigen is a glycosyl part of a phenolic glycolipid PGL in a cell wall of mycobacterium bovis, the polysaccharide antigen has a clear and single chemical structure, can be prepared in a large scale and efficiently through a chemical synthesis method, and effectively solves problems of a complex natural extraction process, non-uniform structure, limited yield and the like. The polysaccharide antigen can be used as a core immunogen and is used for preparation of a mycobacterium PGL polysaccharide conjugate vaccine, provides a stable and controllable key raw material for tuberculosis vaccine research and development, and has a good industrial application prospect.

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

The present disclosure provides novel methods for serotype-specific analysis of compositions comprising one or more polysaccharides. The polysaccharide content can exist as free polysaccharides, or polysaccharide in other forms, such as polysaccharides attached to other molecules or biologics.

The disclosures of the invention are directed to the manufacture of effective, affordable vaccines that are globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA COVID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.1, BA.2, and BA.4 / BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

The present invention relates to an improved method for the high-yield production of crm197 using a manipulated strain of Corynebacterium diphtheriae with an increased copy number of the crm197 gene, wherein the method comprises cultivating the strain in a medium free of animal-derived components containing one or more amino acids.

The invention relates to the technical field of immunity, and discloses a novel carrier protein and application thereof. A novel carrier protein is designed, the amino acid sequence of the novel carrier protein is shown as SEQ ID NO: 1, the novel carrier protein is obtained by coding nucleotide shown as SEQ ID NO: 2, the ACYW135 group meningococcus polysaccharide conjugate vaccine prepared by using the carrier protein has the characteristics of simplicity and high efficiency, and the prepared ACYW135 group meningococcus polysaccharide conjugate vaccine has a good effect.